Streetbeat News

Stock Prices

ENVB

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also recently obtained a US patent for another drug candidate, EB-002, aimed at treating neurological disorders.

Portfolio Pulse from Nina Zdinjak

July 25, 2024 | 12:00 pm

AAPL

STM

TSLA

STMicroelectronics (STM), a supplier for Tesla (TSLA) and Apple (AAPL), reported a 25.3% YoY revenue decline for Q2 2024, beating analyst estimates. Despite beating EPS estimates, the stock plunged due to weak performance in industrial and automotive sectors. STM's outlook for Q3 and fiscal 2024 is below consensus estimates.

Portfolio Pulse from Anusuya Lahiri

July 25, 2024 | 11:59 am

ETHE

FETH

GBTC

IBIT

Bitcoin and Ethereum experienced significant price drops, with Bitcoin falling over 3% and Ethereum plunging below $3,200. The decline was linked to a broader market downturn affecting U.S. technology stocks. Ethereum ETFs saw substantial outflows, while Bitcoin ETFs recorded mixed inflows and outflows.

Portfolio Pulse from Murtuza Merchant

July 25, 2024 | 11:54 am

RTO

Rentokil Initial continues to expect organic revenue growth in North America within the guided 2-4% range for the full year, albeit at the lower end.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:48 am

CMMB

Chemomab Therapeutics has announced a private placement of $10 million, selling 4,188,867 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 3,908,300 ADSs. The purchase price is $1.235 per share, reflecting the average share price on Nasdaq for the last 4 trading days. The private placement is expected to close around July 26, 2024, subject to customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:47 am

CMMB

Chemomab Therapeutics reported positive topline results from the Phase 2 SPRING trial of CM-101 for primary sclerosing cholangitis, achieving its primary endpoint with demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:45 am

META

Mark Zuckerberg, CEO of Meta Platforms Inc. (NASDAQ:META), dismissed rumors that his unusual tan is related to a new augmented-reality device called 'Orion.' Speculation arose after an interview where Zuckerberg appeared with a distinctive tan, but he clarified it was just from wearing Ray-Ban sunglasses. The news also highlighted Meta's AI capabilities and Zuckerberg's criticism of Apple.

Portfolio Pulse from Ananya Gairola

July 25, 2024 | 11:45 am

EVBN

GLSI

UBFO

Insiders have made notable purchases in United Security Bancshares, Evans Bancorp, and Greenwich LifeSciences, indicating confidence in these companies' prospects. United Security Bancshares' Director acquired $1.12 million worth of shares, Evans Bancorp's 10% owner bought $219,179 worth of shares, and Greenwich LifeSciences' CEO and CFO purchased $23,835 worth of shares.

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 11:43 am

ASTS

AST SpaceMobile has completed its first five commercial satellites, named Bluebirds. Each satellite has a communications array of 693 square feet and is ready for shipment to Cape Canaveral in early August, with a launch window in September.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:42 am

AAPL

Apple Inc. (NASDAQ:AAPL) has dropped from third to sixth place in the Chinese smartphone market, with its market share falling to 14% in Q2 2024. Meanwhile, Huawei has seen a 41% increase in shipments, driven by the launch of its Pura 70 series. Apple faces intense competition and has increased discounting efforts to regain market share.

Portfolio Pulse from Rounak Jain

July 25, 2024 | 11:42 am